Why the study?
Are ICDs for primary prevention of sudden death in heart failure cost-effective compared to other recommended therapies?
Are ICDs for primary prevention of sudden death in heart failure cost-effective compared to other recommended therapies?
Answers are grounded in this paper and cite their sources.
This editorial challenges the prevailing cost-effectiveness models of primary prevention ICDs in heart failure, suggesting they may be less cost-effective than medical therapies.
2][3] The current cost, multiplied by the prevalence of heart failure deemed high-risk, threatens to make this one enterprise the highest priced intervention for the Medicare population.The elegant cost-effectiveness analysis contributed by Dr Mark and colleagues from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) in this issue of Circulation provides an exemplary insight into this challenge. 4These investigators' favorable conclusions are consistent with those from a meta-analysis by Sanders et al 5 and with the slightly more conservative implications from the recent cost-effectiveness analysis of the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II by Zwanziger et al. 6 Article p 135This editorial will offer an alternative conclusion based on both back-of-the-envelope estimations and scrutiny of model assumptions regarding different phases of survival for heart failure populations.ICDs for primary prevention of sudden death in the heart failure population may be less costeffective than other recommended heart failure therapies, which are prescribed to modify disease progression and symptoms, decreasing costly hospitalizations as well as mortality.
No takes yet. Share an insight, caveat, or question.
Lynne W. Stevenson (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: